Janssen to expand its Cork plant with the possible creation of 180 jobs

0

Janssen Sciences Ireland is expanding its biopharmaceutical supply chain facility in Ringaskiddy, Co Cork.

The facility, part of the Johnson & Johnson group, will see an investment of 150 million euros.

Some 180 full-time jobs in facilities, engineering, quality, manufacturing and regulatory affairs could be created through the expansion.

Construction began in early 2022 and will take approximately two years. Up to 300 people will be employed during the construction period.

The site opened in 2005 and employs more than 700 people to manufacture drugs for immunology and oncology patients.

The Cork plant makes drugs that treat rheumatoid arthritis, Crohn’s disease, psoriasis, psoriatic arthritis and multiple myeloma, which is a form of blood cancer affecting the white blood cells made in the bone marrow.

The expansion is supported by the government through IDA Ireland.

The announcement follows a €300 million investment in 2017, which saw the construction of a full-scale manufacturing suite at the site. This sequel will soon begin commercial operations after obtaining all necessary manufacturing approvals.

Tánaiste Leo Varadkar said the investment was “fantastic news” for Cork and for patients around the world who use the medicines made at Ringaskiddy.

“I am really proud of the thriving life sciences sector in Ireland. An investment like this demonstrates the strength of the talent we have here. I wish the team well and thank them for their continued commitment to Ireland.

Martin Shanahan, Managing Director of IDA Ireland, said Ringaskiddy is part of the highly successful life sciences cluster that has thrived in the South West region for many years.

“The new investment announced today, which will have an extremely positive economic impact on the region, both in the construction phase and on completion of the project, is welcome.”


Source link

Share.

Comments are closed.